" class="no-js "lang="en-US"> Jérémie Mariau - Medtech Alert
Friday, September 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Jérémie Mariau

Jérémie Mariau

About Jérémie Mariau

After a graduation from a life science engineering school degree and a MSc in Human genetics and cellular biology, spent 15 years in the biotech/biopharma industry. Previously CEO of ILTOO Pharma, and COO of Alfact Innovation.

Related Story

Diseases

 Thabor Therapeutics Secures €2 Million in Deep Tech Financing From Bpifrance | Pharmtech Focus

Thabor Therapeutics Secures €2 Million in Deep Tech Financing From Bpifrance

July 7 2022

Thabor Therapeutics, a company developing an innovative treatment for patients living with chronic mucosal inflammatory […]

Appointments

 Thabor Therapeutics Appoints Jérémie Mariau as Ceo | Pharmtech Focus

Thabor Therapeutics Appoints Jérémie Mariau as Ceo

May 18 2022

Thabor Therapeutics, a company developing an innovative treatment for patients living with chronic mucosal inflammatory […]